Plozasiran is an APOC-III-directed RNA interaction indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). It is available as injection for subcutaneous use. MedsAcross supplies Plozasiran for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). REDEMPLO is an apolipoprotein C-III ( apoC-III )-directed small interfering ribonucleic acid (siRNA) indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).
Source: US FDA prescribing information
Plozasiran is a siRNA conjugated with GalNAc that degrades the apoC-III mRNA through the RNA interference mechanism resulting in reduced levels of hepatic and serum apoC-III protein. Reduction of apoC- III protein leads to increased clearance of serum triglycerides.
Source: US FDA prescribing information
The recommended dosage of REDEMPLO is 25 mg injected subcutaneously once every 3 months. Inject REDEMPLO subcutaneously into the front of the thigh or abdomen. The outer area of the upper arm can be used as an injection site if a healthcare provider or caregiver administers the injection.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and >5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.
Source: US FDA prescribing information
Storage Store REDEMPLO refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton, until ready for use. REDEMPLO prefilled syringe can also be kept at room temperature at 20°C to 25°C (68°F to 77°F) in the original carton for up to 30 days. If not used within the 30 days stored at room temperature, discard REDEMPLO.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Plozasiran, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Redemplo 50 mg/1 mL injectionSubcutaneous Cold chain | Arrowhead Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 1 presentations of Plozasiran and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Plozasiran, including Redemplo.
Yes. The US FDA first approved Plozasiran on 18 November 2025, according to Drugs@FDA.
Yes. Plozasiran has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Plozasiran must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Plozasiran is classified under ATC code C10AX (Cholesterol and lipid-lowering medicines, subgroup C10A, subgroup C10AX).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.